Literature DB >> 27246313

Promoter Variation and Expression Levels of Inflammatory Genes IL1A, IL1B, IL6 and TNF in Blood of Spinocerebellar Ataxia Type 3 (SCA3) Patients.

Mafalda Raposo1,2,3, Conceição Bettencourt4,5, Amanda Ramos6,7,8, Nadiya Kazachkova6,7,8, João Vasconcelos9, Teresa Kay10, Jácome Bruges-Armas7,8,11, Manuela Lima6,7,8.   

Abstract

Age at onset in spinocerebellar ataxia type 3 (SCA3/MJD) is incompletely explained by the size of the CAG tract at the ATXN3 gene, implying the existence of genetic modifiers. A role of inflammation in SCA3 has been postulated, involving altered cytokines levels; promoter variants leading to alterations in cytokines expression could influence onset. Using blood from 86 SCA3 patients and 106 controls, this work aimed to analyse promoter variation of four cytokines (IL1A, IL1B, IL6 and TNF) and to investigate the association between variants detected and their transcript levels, evaluated by quantitative PCR. Moreover, the effect of APOE isoforms, known to modulate cytokines, was investigated. Correlations between cytokine variants and onset were tested; the cumulative modifier effects of cytokines and APOE were analysed. Patients carrying the IL6*C allele had a significant earlier onset (4 years in average) than patients carrying the G allele, in agreement with lower mRNA levels produced by IL6*C carriers. The presence of APOE*ɛ2 allele seems to anticipate onset in average 10 years in patients carrying the IL6*C allele; a larger number of patients will be needed to confirm this result. These results highlight the pertinence of conducting further research on the role of cytokines as SCA3 modulators, pointing to the presence of shared mechanisms involving IL6 and APOE.

Entities:  

Keywords:  Cytokines; MJD; Polyglutamine disease; mRNA levels

Mesh:

Substances:

Year:  2016        PMID: 27246313     DOI: 10.1007/s12017-016-8416-8

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  24 in total

Review 1.  Machado-Joseph Disease: from first descriptions to new perspectives.

Authors:  Conceição Bettencourt; Manuela Lima
Journal:  Orphanet J Rare Dis       Date:  2011-06-02       Impact factor: 4.123

2.  Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha.

Authors:  Roberto Dominici; Monica Cattaneo; Giulia Malferrari; Davide Archi; Claudio Mariani; Luigi Maria Edoardo Grimaldi; Ida Biunno
Journal:  Immunogenetics       Date:  2002-03-19       Impact factor: 2.846

3.  Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains.

Authors:  B O Evert; I R Vogt; C Kindermann; L Ozimek; R A de Vos; E R Brunt; I Schmitt; T Klockgether; U Wüllner
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

4.  Neuronal intranuclear inclusions, dysregulation of cytokine expression and cell death in spinocerebellar ataxia type 3.

Authors:  B O Evert; J Schelhaas; H Fleischer; R A I de Vos; E R Brunt; W Stenzel; T Klockgether; U Wüllner
Journal:  Clin Neuropathol       Date:  2006 Nov-Dec       Impact factor: 1.368

5.  Influence of interleukin-1beta gene polymorphism on age-at-onset of spinocerebellar ataxia 6 (SCA6) in Japanese patients.

Authors:  M Nishimura; H Kawakami; H Maruyama; Y Izumi; S Kuno; R Kaji; S Nakamura
Journal:  Neurosci Lett       Date:  2001-07-13       Impact factor: 3.046

6.  Improvement in the molecular diagnosis of Machado-Joseph disease.

Authors:  P Maciel; M C Costa; A Ferro; M Rousseau; C S Santos; C Gaspar; J Barros; G A Rouleau; P Coutinho; J Sequeiros
Journal:  Arch Neurol       Date:  2001-11

7.  Searching for modulating effects of SCA2, SCA6 and DRPLA CAG tracts on the Machado-Joseph disease (SCA3) phenotype.

Authors:  L Jardim; I Silveira; M L Pereira; M do Céu Moreira; P Mendonça; J Sequeiros; R Giugliani
Journal:  Acta Neurol Scand       Date:  2003-03       Impact factor: 3.209

8.  Segregation distortion of wild-type alleles at the Machado-Joseph disease locus: a study in normal families from the Azores islands (Portugal).

Authors:  Conceição Bettencourt; Raquel Nunes Fialho; Cristina Santos; Rafael Montiel; Jácome Bruges-Armas; Patrícia Maciel; Manuela Lima
Journal:  J Hum Genet       Date:  2008-02-20       Impact factor: 3.172

9.  Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3.

Authors:  Bernd O Evert; Ina R Vogt; Ana M Vieira-Saecker; Lucia Ozimek; Rob A I de Vos; Ewout R P Brunt; Thomas Klockgether; Ullrich Wüllner
Journal:  J Neuropathol Exp Neurol       Date:  2003-10       Impact factor: 3.685

10.  Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein.

Authors:  Stephanie K Hall; David G Perregaux; Christopher A Gabel; Thasia Woodworth; L Kathryn Durham; T W F Huizinga; F C Breedveld; Albert B Seymour
Journal:  Arthritis Rheum       Date:  2004-06
View more
  6 in total

Review 1.  Spinocerebellar ataxias: prospects and challenges for therapy development.

Authors:  Tetsuo Ashizawa; Gülin Öz; Henry L Paulson
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

2.  Selection of Reference Genes for Normalization of Gene Expression Data in Blood of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 (MJD/SCA3) Subjects.

Authors:  Ana F Ferreira; Mafalda Raposo; João Vasconcelos; Maria do Carmo Costa; Manuela Lima
Journal:  J Mol Neurosci       Date:  2019-07-08       Impact factor: 3.444

Review 3.  Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.

Authors:  Kritika Raj; Ravi Shankar Akundi
Journal:  Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.590

Review 4.  Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view.

Authors:  Giulia Coarelli; Alexis Brice; Alexandra Durr
Journal:  F1000Res       Date:  2018-11-12

5.  A Variant in Genes of the NPY System as Modifier Factor of Machado-Joseph Disease in the Chinese Population.

Authors:  Dongxue Ding; Zhao Chen; Chunrong Wang; Xiang Tang; Lulu Zhang; Qi Fang; Rong Qiu; Hong Jiang
Journal:  Front Aging Neurosci       Date:  2022-02-03       Impact factor: 5.750

6.  Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases.

Authors:  Daniela Scarabino; Liana Veneziano; Alessia Fiore; Suran Nethisinghe; Elide Mantuano; Hector Garcia-Moreno; Gianmarco Bellucci; Nita Solanky; Maria Morello; Ginevra Zanni; Rosa Maria Corbo; Paola Giunti
Journal:  Antioxidants (Basel)       Date:  2022-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.